Search
GIP receptor agonist; gastric inhibitory polypeptide receptor agonist; glucose-dependent insulinotropic polypeptide receptor agonist; GIPR agonist
Indications:
- treatment of diabetes mellitus type-2 in the dual function hypoglycemic agent tirzepatide
Interactions
drug interactions
drug adverse effects of hypoglycemic agents
Related
gastric inhibitory polypeptide receptor; GIP receptor; GIP-R; glucose-dependent insulinotropic polypeptide receptor (GIPR)
gastric inhibitory polypeptide; glucose-dependent insulinotropic polypeptide (GIP)
Specific
retatrutide
tirzepatide (Mounjaro, Zepbound)
General
parenteral hypoglycemic agent
References
- Fisman EZ, Tenenbaum A.
The dual glucose-dependent insulinotropic polypeptide (GIP) and
glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide:
a novel cardiometabolic therapeutic prospect.
Cardiovasc Diabetol. 2021 Nov 24;20(1):225.
PMID: 34819089 PMCID: PMC8613929 Free PMC article.
- Gasbjerg LS, Rosenkilde MM, Meier JJ, Holst JJ, Knop FK.
The importance of glucose-dependent insulinotropic polypeptide receptor
activation for the effects of tirzepatide.
Diabetes Obes Metab. 2023 Nov;25(11):3079-3092.
PMID: 37551549 Review.